HomeAI · summaries
Storia in 3 fonti
Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray
Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis effectively. RYALTRIS combines antihistamine and corticosteroid in one formulation. This marks a significant step in expanding access to the treatment.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA expands Ryaltris approval to include children aged 6 to 11 years
The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged…
- ·
thehindubusinessline.com
Glenmark gets US approval for expanded paediatric use of SAR drug
Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older
